Orphazyme confirms delisting in the US

On Friday, Orphazyme’s American Depositary Shares will no longer be tradable on the Nasdaq exchange in the US.
Photo: Nick Chong/Unsplash
Photo: Nick Chong/Unsplash
by marketwire, translated by daniel pedersen

After market closing on Thursday, there will be no more trading of Danish biotech firm Orphazyme’s secondary shares in the US, the company reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading